The global multiple myeloma market size was estimated to be US$ 19.5 billion in 2020 and is expected to reach US$ 30.2 billion by 2031 at a CAGR of 4.1%.
As indicated by myeloma UK, in myeloma, plasma cells become strange, duplicate wildly and delivery just one sort of neutralizer known as para protein, which has no helpful traits present. It is not unexpected, through the figuring of this para protein, that myeloma is diagnosed and identified.
The disease happens in the bone marrow and regularly brings about broad bone annihilation with osteolytic injuries, osteopenia, and additionally fractures. Different entanglements related with the disease likewise incorporate high calcium hyperlipidemia, renal complications, frailty, and infections caused in various other organs. Multiple myeloma is a cancer of the blood segments like plasma cells, officially known as Kahler's disease.
As articulated by WHO, Cancer is a primary reason of deaths around the world, registering around 11.8 million deaths in 2020. Around the world, around 1 of every 6 deaths is because of cancer. Complications associated with treating geriatric patients are driving the demand for effective treatments, for example, rebuilding methodology including transfusion of blood components and point of care progressions.
Launching of medications each year and latest updates noted in drugs and biotechnological areas or enterprises are major aspects driving the market development. The evolution of new medications and the use of autologous hematopoietic undeveloped cell transplantation have altogether improved the diagnosis of multiple myeloma.
In any case, restricted income along with lesser financial aid combined with high treatment cost essentially and patent lapse are a portion of the eye-catching factors that are expected to hinder the development of this market during 2023-2032.
Global Multiple Myeloma Market Value Share Analysis, by Geography (2022)
The report titled “Global Multiple Myeloma Market - Global Market Share, Trends, Analysis and Forecasts, 2023-2032”, wherein 2021 is the historic period, 2022 is the base year, and 2023 to 2032 is forecast period. Additionally, the study takes into consideration the competitive landscape, wherein the report would provide company overview and market outlook for leading players in the Global Multiple Myeloma Market. Furthermore, the report would reflect the key developments, global & regional sales network, business strategies, research & development activities, employee strength, and key executive, for all the major players operating in the market.
The global Multiple Myeloma market is segmented based on type, treatment, route of administration, end-users and distribution channel, and region. Based on type, the Multiple Myeloma market is segmented into smouldering multiple myeloma and active multiple myeloma and Others. Based on treatment, the Multiple Myeloma market is segmented into chemotherapy, targeted therapy, corticosteroids, immunomodulatory agents, and Others. Based on route of administration, the Multiple Myeloma market is segmented into oral, parenteral and Others. Based on end-users, the Multiple Myeloma market is segmented into hospitals, homecare, specialty centers and Others. Based on distribution channel, the Multiple Myeloma market is segmented into hospital pharmacy, online pharmacy, and retail pharmacy.
Based on geography, the Global Multiple Myeloma Market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South America. North America is sub-segmented into the United States, Canada, and Rest of North America. Europe is sub-segmented into Germany, United Kingdom, Italy, France, Spain, and Rest of Europe. Asia Pacific is sub-segmented into China, Japan, India, Australia, and Rest of Asia Pacific. Middle East & Africa is sub-segmented into Saudi Arabia, UAE, South Africa, and Rest of Middle East & Africa. South America is sub-segmented into Brazil and Rest of South America.
The research provides in-depth analysis of prominent players holding majority share of the global market with a focus on all operating business segment and would identify the segment of the company focusing on Global Multiple Myeloma Market. Further, market share of prominent companies in the Global Multiple Myeloma Market would also be estimated.
The study takes into consideration the key competitive information such as business strategy, product portfolio, key development, swot analysis, and research and development focus of all the Multiple Myeloma companies. The Global Multiple Myeloma Market study would take into consideration the participants engaged throughout the supply chain and value chain of the market, along with their contribution.
Product portfolio would focus on all the products under the Multiple Myeloma business segment of the company. Similarly, the recent development section would focus on the latest developments of company such as strategic alliances and partnerships, merger and acquisition, new product launched and geographic expansion in the Global Multiple Myeloma Market.
The key players of the Global Multiple Myeloma Market are Johnson & Johnson Services Inc, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, AbbVie Inc., Novartis AG, Bristol-Myers Squibb Company, Eagle Pharmaceuticals, Inc, Fresenius Kabi AG, Teva Pharmaceutical Industries Ltd, Mylan N.V., Hikma Pharmaceutical Plc, Apotex Inc, Alvogen, Amneal Pharmaceutical Inc, and others.
Global Multiple Myeloma Market Key Segments:
Based on Type
Based on Treatment Type
Based on Route of Administration Type
Based on End-Users Type
Based on Distribution Channel Type
Based on Region
The global multiple myeloma market was worth US$ 19.5 billion in 2020.
The global multiple myeloma market is expected to register a CAGR of 4.1% forecast to 2031.
The global multiple myeloma market is estimated to surpass US$ 30.2 Billion by 2031.
Launching of medications each year and latest updates noted in drugs and biotechnological areas or enterprises are major aspects driving the multiple myeloma market development.
Based on type, the multiple myeloma market is segmented into Smouldering and Active.
Key multiple myeloma market players are Johnson & Johnson Services Inc, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Eagle Pharmaceuticals, Inc, Fresenius Kabi AG, Teva Pharmaceutical Industries Ltd and others.
Copyright © 2024 Same Page Management Consulting Pvt. Ltd. (insightSLICE) | All Rights Reserved